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ABSTRACT
At diagnosis, about 5% of Chronic Myeloid Leukemia (CML) patients lacks 
Philadelphia chromosome (Ph), despite the presence of the BCR/ABL rearrangement. 
Two mechanisms have been proposed about the occurrence of this rearrangement: the 
first one is a cryptic insertion between chromosomes 9 and 22; the second one involves 
two sequential translocations: a classic t(9;22) followed by a reverse translocation, 
which reconstitutes the normal morphology of the partner chromosomes. Out of 398 
newly diagnosed CML patients, we selected 12 Ph-negative cases. Six Ph-negative 
patients treated with tyrosine kinase inhibitors (TKIs) were characterized, in order 
to study the mechanisms leading to the rearrangement and the eventual correlation 
with prognosis in treatment with TKIs. FISH analysis revealed cryptic insertion in 
5 patients and classic translocation in the last one. In more detail, we observed 4 
different patterns of rearrangement, suggesting high genetic heterogeneity of these 
patients. In our cases, the BCR/ABL rearrangement mapped more frequently on 9q34 
region than on 22q11 region, in contrast to previous reports. Four patients, with low 
Sokal risk, achieved Complete Cytogenetic Response and/or Major Molecular Response 
after TKIs therapy. Therapy resistance was observed in one patient with duplication 
of BCR/ABL rearrangement and in another one with high risk. Even if the number 
patient is inevitably low, we can confirm that the rare Ph-negative CML patients do 
not constitute a “warning” category, meanwhile the presence of further cytogenetic 
abnormalities remains an adverse prognostic factor even in TKI era.
INTRODUCTION
Chronic Myeloid Leukemia (CML) is a myelopro- 
liferative disorder characterized by the presence of 
the Philadelphia (Ph) chromosome, produced by the 
reciprocal translocation t(9;22)(q34;q11) [1, 2]. The 
resulting chimeric BCR/ABL fusion gene encodes for 
constitutively active tyrosine kinase protein [3]. A small 
amount of patients (about 5%), displaying typical features 
.of CML, lacks the Ph chromosome by chromosome 
banding analysis (CBA), meanwhile shows BCR/ABL 
rearrangement. These cases are reported as Ph-negative 
(Ph-neg) CML cases and can be identified by fluorescence 
in situ hybridization (FISH) or by molecular analysis [4].
Two mechanisms have been proposed to explain 
how this kind of rearrangement can arise: the first one 
could be a cryptic insertion between chromosomes 9 and 
22; the second mechanism could involve two sequential 
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translocations, in which a standard t(9;22) translocation 
is followed by a reverse translocation with different 
breakpoints, that reconstitutes the normal morphology of 
the partner chromosomes. FISH analysis on metaphases 
shows the fusion BCR/ABL gene on derivative 
chromosome 22 (der(22)) much more frequently than on 
derivative chromosome 9 (der(9)) [5].
In the past, some authors reported that this kind of 
rearrangement was associated with worse prognosis than 
the classic translocation, when the patients were treated 
with conventional chemotherapy and/or α-interferon 
(α-IFN) therapy; while others did not find any differences 
in terms of outcome [6–8]. Moreover to our knowledge, 
only 9 Ph-neg CML cases treated with imatinib have 
been described in 5 previous reports [5, 9–12]. The 
outcome of 2 patients has not been clearly reported. Two 
patients achieved at least Major Cytogenetic Response 
(CgR) after imatinib treatment [9, 11–12], meanwhile 5 
patients failed the treatment, suggesting that they were 
more resistant to imatinib therapy [5, 10]. Among the 
latter, a recent report [10] described two cases with 
fusion genes on both the homologous chromosomes 9 
(Table 1).
We report an analysis of the clinical, cytogenetic and 
molecular characteristics of 6 patients with Ph-neg CML, 
treated with tyrosine kinase inhibitors (TKIs).
RESULTS
At diagnosis, we have analysed 398 CML cases, of 
which 12 (3%) showed normal karyotype by CBA and 
BCR/ABL rearrangement by RT-PCR analysis. Of these, 
only 6 recently diagnosed patients were valuable for CBA, 
FISH and molecular analysis during TKIs therapy.
Detailed baseline genetic characteristics of the 
patients are presented in Table 2. RT-PCR analysis of the 
chimeric BCR/ABL transcript showed b3a2 transcript in 
5 patients and b2a2 in only 1 patient (n.2). In 4 evaluable 
patients, no mutation in ABL gene was found at diagnosis 
and during the following treatment.
Dual-Color Dual Fusion (DCDF) FISH analysis 
revealed BCR/ABL fusion signal on der(9) in 4 patients 
(n.1-4), on der(22) in 1 patient (n.5) and on both derivative 
chromosomes in the last one (n.6).
Three patients (n.2-4), beyond BCR/ABL rearrange-
ment on der(9), revealed a red ABL signal and a green BCR 
signal on the normal chromosomes and a smaller BCR signal 
on der(22), as consequence of the insertion of the BCR 
region into ABL region (Figure 1A). The second smaller 
BCR signal was not observed in 1 patient (n.1) (Figure 
1B). The only patient (n.5) with BCR/ABL fusion signal on 
der(22) showed BCR signal on the normal chromosome 22 
and ABL signals on both chromosome 9 (Figure 1C). The 
classic FISH pattern (2 fusion, 1 ABL and 1 BCR signals) 
was observed in the last patient (n.6, Figure 1D). Therefore, 
4 different FISH signal patterns were observed in 6 patients.
By Tri-Color Dual Fusion (TCDF) FISH analysis, 
the rearrangement was confirmed as insertion of the BCR 
region into the ABL region in the patients with BCR/ABL 
fusion on der(9) (n.1-4) and insertion of the ABL region 
into the BCR region in the patient with BCR/ABL fusion on 
der(22) (n.5). The classic pattern of the last case (n.6) could 
be explained with 2-step mechanism: the first translocation 
involved the classic breakpoints and the second 
translocation with different breakpoints reconstituted the 
affected chromosomes without modifying the fusion gene.
Moreover, 2 patients (n.1 and 3) (33,3%) harbored 
deletions adjacent to the BCR and/or ABL breakpoints: on 
both der(9) and der(22) chromosomes in patient n.1 and 
on der(9) in patient n.3. During the disease progression 
of the patient n.2, FISH analysis revealed the appearance 
of a second clone characterized by two fusion BCR/ABL 
and two BCR signals, that gradually replaced the first 
clone with only one fusion signal. The clonal evolution 
was concomitant with the increase of transcript detected 
by RQ-PCR. By FISH analysis on metaphase, the 2 fusion 
signals were observed on both chromosomes 9 (Figure 2), 
suggesting the duplication of BCR/ABL rearrangement, as 
sign of clonal evolution.
During imatinib therapy, interphase-FISH analysis 
revealed decrease of BCR/ABL positive cells in 3 patients 
(n.1, 3 and 5) and after a median time of 24 months (range 
18-30 months) they reached the Complete CgR (CCgR) 
by FISH, while two patients (n.2 and 6) retained high 
rate of BCR/ABL positive cells by FISH (81,5% and 
79%, respectively). Patient n.2 stopped imatinib because 
of the appearance of intestinal malignancy and later he 
died. Patient n.6 failed imatinib therapy, started nilotinib 
treatment and, at last follow-up, retained Major Molecular 
Response (MMR).
The last one (n.4) relapsed after 4 years from 
allogeneic stem cell transplantation (SCT), achieved 
CCgR and complete MR after 6 months of imatinib 
therapy. Six years later, she lost MMR, started dasatinib 
and then nilotinib treatments, but she died in Partial CgR 
after the second allogeneic SCT.
DISCUSSION
As is known, FISH analysis is an efficient tool to 
characterize Ph-neg rearrangements, because it allows to 
detect the occurrence of BCR/ABL rearrangement and to 
monitor the response to therapy [13].
To our knowledge, here we present the largest 
monocentric series of the of Ph-neg CML patients treated 
with TKIs therapies and we confirm their low frequency 
(3%).
In Ph-neg CML cases, the BCR/ABL fusion gene 
is often located on der(22) and rarely on der(9), indeed 
its presence on der(9) has been reported only in 24 Ph-
neg CML patients [4–10]. Conversely, in our series 4/6 
(66,7%) Ph-neg CML cases showed the rearrangement 
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on der(9) and one displayed 2 fusion signals on both 
derivative chromosomes 9 and 22, as in the classic 
translocation.
Regarding the involving mechanisms, previous 
reports considered the cryptic insertion of chromosome 
22, comprising 5’ BCR within the ABL gene or viceversa, 
more probable than two consecutive translocations. The 
insertion seems more likely, since it requires only two 
breaks at 22q11 and one at 9q34, or viceversa, instead of 
four breaks required in double consecutive translocations 
[5]. TCDF BCR/ABL FISH analysis allowed us to clarify 
the mechanisms by which the translocations may take 
place. We have hypothesized cryptic insertion in 5 cases 
and two-translocations mechanism in only one case. The 
observation of 4 different FISH pattern in 6 Ph-neg cases 
suggested high genetic heterogeneity in this subgroup of 
CML patients.
The prognostic significance of the occurrence of 
cryptic Ph translocations has been discussed in previous 
reports, but data regarding the outcome of Ph-neg CML 
patients treated with TKIs are limited. In 4 patients, the 
CgR by FISH analysis was achieved after a median time 
of 24.5 months from the start of imatinib (range 7-40 
months): 3 patients are still in deep MR, while the other 
one lost MMR after 6 years of imatinib. Another patient 
achieved MMR when treated subsequently with nilotinib. 
Two patients had to change TKI because of resistance to 
imatinib and of relapse after SCT.
During imatinib treatment, a not responder patient 
showed duplication of the BCR/ABL rearrangement, 
confirming that this change is an event of clonal evolution. 
The duplication of rearrangement appeared as 2 fusion 
genes on both the homologous chromosomes 9, like in 
2 other cases previously reported [10]. Similarly to our 
Table 1: Ph-neg cases treated with imatinb and outcome reported in literature
Case Sex/Age 
(years)
Pattern 
FISH
del(9q) Location of 
BCR/ABL 
rearrangement
Mechanism of 
rearrangement
Therapy Cytogenetic 
response
Reference
1 unknown 1R2G1F NO der(9) Insertion on 
der(9)
imatinib NR Haigh S. et al, 
2004 [5]
2 unknown 2R1G1F NO der(22) Insertion on 
der(22)
imatinib NR Haigh S. et al, 
2004 [5]
3 unknown 2R1G1F NO der(9) 2-step 
mechanism
imatinib NR Haigh S. et al, 
2004 [5]
4 M/62 1R2G1F
1R2G2F 
(trisomy 9)
unknown der(9) 2-step 
mechanism
imatinib CCgR Fugazza G. et 
al, 2005 [9]
5 M/27 1R2G1F 
(80%)
2G2F (20%)
NO der(9) Insertion on 
der(9)
hydroxyurea
Imatinib
NR Brahmbhatt 
M. et al, 2014 
[10]
6 M/30 1R2G1F NO der(9) Insertion on 
der(9)
hydroxyurea
Imatinib
NR Brahmbhatt 
M. et al, 2014 
[10]
7 F/47 1R2G1F NO der(9) Insertion on 
der(9)
hydroxyurea 
+ α-IFN
Imatinib
SCT
unknown Batista A.S. 
et al, 2005 
[11]
8 F/31 1R1G1F YES der(22) Insertion on 
der(22)
hydroxyurea
SCT
Imatinib
unknown Batista A.S. 
et al, 2005 
[11]
9 M/27 1R2G1F
1R1G2F
YES
NO
der(9)
der(9)+der(22)
Insertion on 
der(9)
2-step 
mechanism
Imatinib MCgR Bennour A. et 
al, 2011 [12]
Abbreviations: R=red signal; G=green signal; F=fusion signal; der(9)= derivative of chromosome 9; der(22)= derivative 
of chromosome 22; SCT= stem cell transplantation; NR= no response; CCgR= Complete Cytogenetic Response; 
MCgR= Major Cytogenetic Response.
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case, the 2 patients did not achieve CgR. The amplification 
of BCR/ABL rearrangement (as the duplication of Ph 
chromosome) has been always considered a mechanism 
of resistance to the therapy and, therefore, associated with 
adverse prognosis, like other additional chromosomal 
abnormalities [14, 15].
Moreover, deletions of a sizable portion of the 
der(9) have been described in 10-15% of CML patients. 
Figure 1: DCDF FISH analysis showing: A. 1R2G1F signal pattern and the BCR/ABL fusion gene on der(9); B. 1R1G1F signal 
pattern and the BCR/ABL fusion gene on der(9) C. 2R1G1F signal pattern and the BCR/ABL fusion gene on der(22); D. 1R1G2F signal 
pattern and the BCR/ABL fusion genes on der(9) and der(22).
Table 2: FISH and molecular features of the Ph-neg patients
Patients FISH
signal patterna
Location of BCR/
ABL fusion gene
Molecular transcript Mutational status
1 1R1G1F chr. 9 b3a2 unknown
2 1R2G1F chr. 9 b2a2 wild-type
3 1R2G1F chr. 9 b3a2 unknown
4 1R2G1F chr. 9 b3a2 wild-type
5 2R1G1F chr. 22 b3a2 wild-type
6 1R1G2F chr. 9 and 22 b3a2 wild-type
aUsing Vysis LSI BCR/ABL dual-color, dual fusion FISH probe system: R=red signal, G=green signal, F=fusion signal
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A recent paper asserted that deletions of der(9) do not 
influence the response and the outcome of CML in early 
CP treated with imatinib [16]. De Melo et al. [17] reported 
deletions of ABL or BCR regions in 21% of Ph-neg CML 
cases, concluding that the loss of genomic material is an 
effect of any DNA breakage event at chromosome 9q34 
and 22q11 regardless of the mechanism of chromosomal 
rearrangement. In our cases, deletions occur in 2 patients 
(n.1 and 3): this rate is superior to that found in Ph+ 
patients [16], although we have to consider the low 
number of cases. However both our patients achieved 
MMR.
We have observed that 5 out of 6 Ph-neg CML 
patients achieved CCgR and/or MMR during TKIs 
treatment, also as second line of therapy. Clearly, the 
low number of cases and the heterogeneity of the therapy 
limit the analysis. We have to highlight that the adverse 
outcome of 2 patients could be related to their Sokal risk: 
intermediate and high, respectively. Moreover, the only 
patient with intermediate Sokal risk showed duplication 
of BCR/ABL rearrangement during the outcome.
In conclusion, most Ph-neg CML patients benefited 
from TKIs therapy and achieved CCgR and MMR, 
showing outcome similar to that of Ph+ CML patients.
Ph-neg rearrangements could be considered variant 
BCR/ABL rearrangements, although they involve only 
the chromosomes 9 and 22, differently to “real” variant 
translocations. As the latter [18], Ph-neg rearrangement 
does not influence the response to TKIs therapy. We 
confirm that Ph-neg CML patients do not constitute a 
“warning” category in imatinib era, in according to ELN 
2013 recommendations [19, 20].
Only 2 Ph-neg CML patients failed TKIs therapy; in 
one a secondary change occurred, confirming that BCR/
ABL duplication remains a mechanism of resistance to the 
therapy, also in TKI era.
Figure 2: DCDF FISH analysis showing 1R1G2F signal pattern and the BCR/ABL fusion genes on both chromosomes 9.
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MATERIALS AND METHODS
Patients
The clinical features of the Ph-neg patients are 
reported in Table 3. They were 5 males and 1 female, with 
a median age of 43.5 years (range 22-68); Sokal risk was 
low in 4 patients, intermediate in 1 patient and high in the 
last one; the median WBC count was 102.5*109/l (range 
32.9-283); the median PLT count was 324*109/l (range 92-
560); epatosplenomegaly was observed in all patients, but 
one (n.1).
Cytoreduction was started with hydroxyurea in 3 
patients: later, 2 patients (n.1 and n.2) were treated with 
imatinib; meanwhile the other patient (n.4) underwent to 
allogeneic SCT, after 4 years she relapsed in accelerated 
phase and started imatinib therapy; then she was treated 
with dasatinib and afterwards with nilotinib. She died after 
second allogeneic SCT. Two other patients (n.5 and 6) 
were treated frontline with imatinb and the last one (n.3) 
started imatinib after α-IFN treatment.
The study is performed according to Good Clinical 
Practices and Declaration of Helsinki.
Cytogenetics analysis
Cytogenetic studies were performed on bone 
marrow samples after short term (24 and/or 48 hours) 
cultures. Karyotypes were examined after GAW banding 
techniques. In each case, at least 20 metaphases were 
analysed and the karyotypes were described according 
to the criteria of the International System for Human 
Cytogenetic Nomenclature [21].
FISH analysis
FISH was performed on bone marrow cells 
prepared according to standard cytogenetic techniques 
and using LSI BCR/ABL DCDF and LSI BCR/ABL + 
9q34 TCDF translocation probes (Vysis Inc, Downers 
Grove, IL, USA) and ON BCR/ABL t(9;22), triple-
color probe (Kreatech Biotechnology, Amsterdam, 
Netherlands). FISH was carried out according to the 
manufacturer’s instructions, with slight modifications. 
FISH analysis was performed at least on 200 nuclei and 
on metaphases to confirm the interphase FISH pattern 
and to localize the rearrangement.
Table 3: Clinical characteristics of the patients
Patients Sex Agea
(years)
Sokal risk Epato-
splenomegaly
Count at diagnosis Treatment Last 
detail
Follow-
up
(months)
WBC
(109/L)
PLT
(109/L)
Blasts  
BM (%)
Eo/ 
Bso (%)
1 M 22 low No 52,3 398 1 3 hydroxyurea, 
imatinib
CCgR, 
MR4
156
2 M 68 intermediate Yes 93 92 / / hydroxyurea, 
imatinib
diedb 68
3 M 44 low Yes 32,9 250 / 0,6 α-interferon, 
imatinib
CCgR, 
CMR, 
MR5
144
4 F 41 high Yes 283 560 / 3 hydroxyurea, 
alloSCT, 
imatinib, 
dasatinib, 
nilotinib
diedc 105
5 M 47 low Yes 112 469 <5 0.75 imatinib MMR, 
MR4.5
132
6 M 43 low Yes 176 184 1 1,5 imatinib, 
nilotinib
MMR lost
aat diagnosis; bintestinal malignancy; cin therapy with nilotinib;
Abbreviations: SCT: stem cell transplantation; CCgR= Complete Cytogenetic Response; MR= Molecular Response; 
CMR= Complete Molecular Response; MMR= Major Molecular Response.
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Since at diagnosis FISH pattern of the most cases 
shows only 1 fusion signal by FISH analysis, CgR was 
defined by the rate of cells with 1 fusion signal. The value 
of false positive cut-off was calculated on 68 normal 
controls resulting in 10% (mean+3DS) [22].
RT-PCR and RQ-PCR
Qualitative RT-PCR for BCR/ABL transcript was 
performed at diagnosis, in order to determine the type of 
transcript.
The RQ-PCR was performed to monitor the amount 
of BCR/ABL transcript during the therapy, using the 
ABIPRISM7700 Sequence Detector (Perkin Elmer, 
Faster City, CA). ABL was used as housekeeping gene to 
correct for differences in RNA quality and/or RT efficacy. 
All experiments were performed in duplicate and the 
results were expressed as percent ratio to ABL. The BCR/
ABL to ABL ratios were additionally multiplied by the 
conversion factor of the Bologna lab to set the results on 
the International Scale (IS). Samples yielding an ABL 
threshold cycle (Ct) greater than 30, which corresponded 
to fewer than 1,000 ABL transcript copies, were 
considered to have degraded RNA and were discarded.
The following criteria have been used to define the 
molecular response (MR) [19, 23]:
MR4= either detectable disease ≤0.01% BCR-ABLIS 
or undetectable disease in cDNA with ≥10000 ABL1 or 
≥24000 GUSB transcripts (numbers of ABL or GUSB 
transcripts in the same volume of cDNA used to test for 
BCR-ABL);
MR4,5= either detectable disease ≤0.0032% BCR-
ABLIS or undetectable disease in cDNA with ≥32000 
ABL1 or ≥77000 GUSB transcripts;
MR5= either detectable disease ≤0.001% BCR-
ABLIS or undetectable disease in cDNA with ≥100000 
ABL1 or ≥240000 GUSB transcripts.
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